Validation of the Danish Translation of the Revised Mystical Experience Questionnaire (MEQ30) and Possible Impact of Setting, Dose and Intention
Oliver Rumle Hovmand, Mathias Ebbesen Jensen, Tobias Søgaard Juul, M. Madsen, Patrick M. Fisher, Dea Siggaard Stenbæk
Journal of Psychoactive Drugs January 15, 2024 DOI: 10.1080/02791072.2024.2302186 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Validation study Peer reviewed |
|---|---|
| Sample size | 1,381 |
| Population | Danish-speaking healthy volunteers receiving psilocybin in a laboratory setting and recreational users of psychedelics |
| Intervention | Psilocybin |
| Topics | Mysticism Psilocybin Mystical experience |
| Keywords | Danish Confirmatory factor analysis Clinical psychology |
| Citations | 6 |
| Key points | The Danish MEQ30 is a valid and reliable tool for assessing mystical-type experiences, with a four-factor structure providing the best fit and scores correlating with dose and spiritual or religious intention. |
Abstract
Research suggests positive changes in both well-being and psychiatric symptoms following a psychedelic experience. One explanation may be the ability of psychedelic compounds to occasion mystical-type experiences. The Revised Mystical Experiences Questionnaire (MEQ30) is designed to assess the intensity and quality of such experiences. We examined the validity, reliability, and factor structure of a Danish translation of the MEQ30 in one sample of healthy volunteers receiving psilocybin in a laboratory setting (N = 47) and two samples of recreative users of psychedelics, in which MEQ30 was reported retrospectively through an online survey based on their most recent experience with psilocybin (N = 834) or their most memorable experience with any psychedelic (N = 500). We conducted a confirmatory factor analysis of the previously suggested factor structures, calculated alpha and omega, and tested the associations between MEQ30 total score and setting, intention and dose. We found excellent internal reliability estimates across all samples, and confirmatory factor analysis showed that a four-factor structure, had the best, fair fit to the data. We further found that the MEQ30 total score was correlated with dose and a spiritual/religious intention, but not with setting. The Danish MEQ30 seems to be a valid tool for accessing mystical-type experiences among Danish-speaking individuals.
Citations in the library
Cited by 6
- Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study Journal of Psychopharmacology February 28, 2025
- Altered states of consciousness in Danish healthy volunteers and recreational users of psilocybin and the possible impact of setting and intention: Danish validation of the five-dimensional altered states of consciousness questionnaire Journal of Psychopharmacology August 13, 2024
- Setting the Stage for the Inner Journey: Unraveling the Interplay of Contextual Factors and the Intensity of Psychedelic-Induced Ego Dissolution. Journal of Psychoactive Drugs February 13, 2025
- Single-Dose Psilocybin Therapy for Alcohol Use Disorder: Pharmacokinetics, Feasibility, Safety, and Efficacy in an Open-Label Study Research Square August 23, 2024
- Assessment of psychedelic--induced states: Norwegian translation and adaptation of the revised Mystical Experience Questionnaire (MEQ-30) Journal of Psychedelic Studies July 12, 2024
and 1 more in the library
Cites 32
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
and 27 more in the library